Improvement of cognitive function by ingestion of cacao flavanol
- Conditions
- ot applicable
- Registration Number
- JPRN-UMIN000046120
- Lead Sponsor
- Shibaura institute of technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 16
Not provided
1.Those who currently suffer from any kind of disease and are undergoing drug treatment 2.Those who have or are being treated for symptoms of dementia or other memory disorder diseases. 3.Those who have been taking medication for the purpose of disease treatment in the past month (excluding history of headache, menstrual cramps, common cold, etc.) 4.Those who have a history of or are currently suffering from serious disorders of the liver, kidney, heart, lungs, blood, etc. 5.Those with comorbidities or history of comorbidities in the digestive organs 6.Patients with severe anemia 7.Those with food allergies (especially milk) 8.Women: Pregnant, lactating, or planning to become pregnant during the study period 9.Persons with alcoholism or other mental disorders 10.Those with a smoking habit 11.Those who may change their lifestyle during the study period 12.Those at risk of developing seasonal allergic symptoms such as hay fever during the test period. 13.Those who have been in the habit of taking functional foods, health foods, or supplements containing the ingredients (polyphenols) of the test foods at present or within the past three months, and those who plan to do so during the test period. 14.Those who have been in the habit of taking drugs, functional foods, health foods, or supplements claiming to have cognitive effects at present or within the past three months. 15.Have received hormone replacement therapy within the past 6 months. 16.Those who have been treated with hospitalization within the past 6 months, or those who are scheduled to be hospitalized during the examination period. 17.Those who are currently participating in other human clinical trials, and those who have been participating in other human clinical trials for less than one month. 18.Those who have not yet completed the second dose of COVID-19 vaccine. 19.Others who are judged by the investigator to be inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy endpoint: Cognitive function test by Cognitrax Safety evaluation: Interview of physical condition after the exam
- Secondary Outcome Measures
Name Time Method